Novo Nordisk

Learn why.

Esperoct^® is indicated for on-demand treatment and control of bleeding episodes, perioperative bleed management, and routine prophylaxis in adults and children with hemophilia A.

EHL products reduce the frequency of infusions,^a but Esperoct^® does more than that...”

—Dr. Tami Singleton

Chief of Pediatric Hematology and Director of the HTC at the Mississippi Center for Advanced Medicine.

Watch the Video

^a With the extended half-life of Esperoct^®, your prophylaxis patients may need up to 50% fewer infusions per year compared to standard half-life rFVIII treatments, 50% fewer if previously dosed every other day; 40% fewer if previously dosed 3x/week.¹

Scroll down and get patients started with Esperoct^®

Selected Important Safety Information

Contraindications

•

Do not use in patients who have known hypersensitivity to Esperoct^® or its components, including hamster proteins

Warnings and Precautions

•

Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct^® and administer appropriate treatment

Please click here or scroll below for additional Important Safety Information.

Introducing the Esperoct^®

Trial Prescription Program

Qualifying patients can access an initial supply of Esperoct^®—at no cost.^b Are your patients eligible?

Get Your Patients Started

^b Patients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.

Have you signed up for your Novo Nordisk account?

	Keep up with important information about Esperoct^® and other treatments.
	Receive the latest product news and information from Novo Nordisk.
	Download, order, and share patient educational materials.

Indications and Usage

Esperoct^® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

•

Esperoct^® is not indicated for the treatment of von Willebrand disease

Important Safety Information (cont’d)

Warnings and Precautions

•

Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct^® or if the expected plasma Factor VIII activity levels are not attained

Adverse Reactions

•

The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information.

References:

1.	Esperoct^® [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.

<%@ include view='hcpColoradoFooter' %>

Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500.

UNSUBSCRIBE NOTICE

If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement.